Boundless Bio (BOLD) Capital Expenditures (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Capital Expenditures of $8000.0 for Q1 2026, down 86.44% year-over-year from $59000.0 in Q1 2025, and down 98.11% quarter-over-quarter from $424000.0 in Q4 2025.
Boundless Bio (BOLD) Capital Expenditures (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Capital Expenditures for 4 consecutive years, with $8000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 86.44% year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $495000.0 (up 31.65% YoY), while the FY2025 annual figure was $546000.0, up 36.5% from the prior year.
- Capital Expenditures eased to $8000.0 in Q1 2026 per BOLD's latest filing, from $424000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.5 million in Q2 2024 and bottomed at -$1.7 million in Q4 2024.
- Historically, Capital Expenditures has averaged $122076.9 across 4 years, with a median of $83000.0 in 2024.
- On a YoY basis, Capital Expenditures climbed as much as 700.0% in 2024 and fell as far as 723.13% in 2024.
- Boundless Bio's Capital Expenditures stood at $268000.0 in 2023, then slumped by 723.13% to -$1.7 million in 2024, then jumped by 125.39% to $424000.0 in 2025, then plunged by 98.11% to $8000.0 in 2026.
- Business Quant data shows BOLD's Capital Expenditures at $8000.0 in Q1 2026, $424000.0 in Q4 2025, and $15000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Boundless Bio | 67.35 Mn | 67.35 Mn | - | 38,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38,000.00 |
| Jun 30, 2026 | 38,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Dec 31, 2025 | 424,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Sep 30, 2025 | 15,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Jun 30, 2025 | 48,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Mar 31, 2025 | 59,000.00 |
| Dec 31, 2024 | -1.67 Mn |
| Dec 31, 2024 | -1.67 Mn |
| Sep 30, 2024 | 483,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 1.50 Mn |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |